Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
NCNA - NuCana plc
0.50(7.69%)9:00:00 PM 1/15/2021
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Stock Chart


  • Although price ZSCore is at a high level but it has returned from prior high level and momentum has slowed down.
  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • RSI is at a high level of 81. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.3. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics


Stock news

    NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

    Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy Safety Profile Continues to be FavorableEDINBURGH, United Kingdom, Jan. 15, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.NuTide:302 is a three-part study investigating NUC-3373, NuCana’s targeted thymidylate sy...

    These 2 Penny Stocks Could Surge Over 300%, Say Analysts

    Risk and reward often travel hand-in-hand, making the stock market both lucrative and dangerous. Among the best exemplars of this axiom are the penny stocks, those equities priced at $5 or less. With that low price comes the potential for extreme gains, as even an incrementally small price increase will translate to a high percentage gain.JPMorgan's Head of Small and Midcap Equity Strategy, Eduardo Lecubarri, sees both the opportunities and dangers in the current market environment – and the gre...

    NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session

    NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

    NuCana Appoints Andrew Kay as Board Chairman

    Pharmaceutical Executive Brings a Wealth of Experience to NuCana’s Board of Directors Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy TherapeuticsEDINBURGH, United Kingdom, Dec. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Andrew Kay as Chairman of its Board of Directors.“We are delighted to welcome Andrew a...

    Is NCNA A Good Stock To Buy Now?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

    The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 30) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) * argenx SE - ADR (NASDAQ: ARGX) * Beam Therapeutics Inc (NASDAQ: BEAM) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BioLife Solutions Inc (NASDAQ: BLFS) * BioNTech SE - ADR (NASDAQ: BNTX) (reacted to reports of imminent approval for its coronavirus ...

    Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist

    Acelarin plus Cisplatin’s High Objective Response Rate and Favorable Safety Profile ConfirmedNuTide:121 Global Phase III Study Recruitment OngoingEDINBURGH, United Kingdom, Nov. 30, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the final results of the Phase Ib study of Acelarin plus cisplatin for patients with advanced biliary tract cancer (ABC-08) have been published online ahead of print in The Oncologist. Encouraging interim data had previously been reported and the final...

    NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update

    Completed Successful $80 million Public Offering Presented Encouraging Data for NUC-3373 and NUC-7738 at the ESMO Virtual Congress 2020EDINBURGH, United Kingdom, Nov. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.As of September 30, 2020, NuCana had cash and cash equivalents of £100.7 million compared to £47.8 milli...